Home Protein Tyrosine Kinase Mertk

Mertk

Other Protein Tyrosine Kinase Related Inhibitors

VEGFR EGFR c-Met PDGFR CSF-1R IGF-1R c-Kit ALK Tie-2 HER2
Cat.No. Product Name Information Product Use Citations Product Validations
S9662 UNC2025 UNC2025 is a potent and orally active dual inhibitor of FLT3 and MER with IC50 of 0.35 nM and 0.46 nM, respectively. This compound also inhibits AXL, TRKA, TRKC, QIK, TYRO3, SLK, NuaK1, Kit (c-Kit) and Met (c-Met) with IC50 of 1.65 nM, 1.67 nM, 4.38 nM, 5.75 nM, 5.83 nM, 6.14 nM, 7.97 nM, 8.18 nM and 364 nM, respectively.
iScience, 2024, 27(7):110226
Commun Biol, 2023, 6(1):916
Int J Mol Sci, 2023, 10.3390/ijms242115903
S7342 UNC2250 UNC2250 is a potent and selective Mer inhibitor with IC50 of 1.7 nM, about 160- and 60-fold selectivity over the closely related kinases Axl/Tyro3.
Journal of Hematology & Oncology, March 20, 2018, 43
Bioact Mater, 2024, 32:427-444
Redox Biol, 2022, 54:102366
Verified customer review of UNC2250
S7325 UNC2881 UNC2881 is a specific Mer tyrosine kinase inhibitor with IC50 of 4.3 nM, about 83- and 58-fold selectivity over Axl and Tyro3, respectively.
Frontiers in Bioengineering and Biotechnology, 2022, 788987
Cell Rep, 2020, 30(11):3671-3681
Cell Reports, 2020, 3671-3681
S6839 MRX-2843 MRX-2843 (UNC2371) is an orally active dual inhibitor of tyrosine kinases MERTK and FLT3 with IC50 of 1.3 nM and 0.64 nM, respectively.
Cancer Immunology Research, 2025, CIR-24-0335
Scientific Reports, 2024, 4125
Scientific Reports, 2024, 14:4125
E1744 UNC5293 UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM.
Nature Communications, 2024, 5292
S0439 UNC2541 UNC2541 is a potent and specific inhibitor of Mer tyrosine kinase (MerTK) that binds in the MerTK ATP pocket with IC50 of 4.4 nM. This compound inhibits phosphorylated MerTK (pMerTK) with EC50 of 510 nM.
S7638 LDC1267 LDC1267 is a highly selective TAM kinase inhibitor with IC50 of <5 nM, 8 nM, and 29 nM for Mer, Tyro3, and Axl, respectively. This compound displays lower activity against Met, Aurora B, Lck, Src, and CDK8.
Genes & Development, October 1, 2020, 1345-1358
Frontiers in Microbiology, June 29, 2020, 1292
Oncotarget, January 5, 2018, 6402-6415
Verified customer review of LDC1267
S7576 UNC2025 HCl UNC2025 HCl is a potent and orally bioavailable dual MER/FLT3 inhibitor with IC50 of 0.74 nM and 0.8 nM, respectively, about 20-fold selectivity over Axl and Tyro3.
bioRxiv, 2025, 2025.07.18.665641
Immunity, 2023, 56(8):1778-1793.e10
International Journal of Molecular Sciences, 2023, 15903
S7014 Merestinib (LY2801653) Merestinib (LY2801653) is a type-II ATP competitive, slow-off inhibitor of Met (c-Met) tyrosine kinase with a dissociation constant (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min(-1) and t1/2 of 525 min. This compound also inhibits MST1R, AXL, ROS1, MKNK1/2, FLT3, MERTK, DDR1 and DDR2 with IC50 of 11 nM, 2 nM, 23 nM, 7 nM, 7 nM, 10 nM, 0.1 nM and 7 nM, respectively.
Mol Oncol, 2025, 19(8):2366-2387
Molecular Oncology, 2025, 2366-2387
NPJ Breast Cancer, 2024, 10(1):65
S8570 CEP-40783 (RXDX-106) CEP-40783 (RXDX-106) is an orally-available, potent and selective TAM(TYRO3, AXL, MER)/Met (c-Met) inhibitor displaying low nanomolar biochemical activity and slow (T1/2 >120 min) inhibitor off-rate in peptide phosphorylation assays and in vitro kinase binding assays, respectively.
Cell Reports, October 05, 2021, 109789
Journal of Clinical Investigation, November 01, 2018, 5034-5055
UNIVERSITY OF CALIFORNIA, 2023,